Nuvectis Pharma (NVCT) Research & Development (2021 - 2026)

Nuvectis Pharma has disclosed Research & Development across 6 years of filings, most recently posting $4.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $4.1 million, up 11.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.6 million (up 33.3% YoY), and the FY2025 annual result was $18.2 million, up 40.52% from the prior year.
• Research & Development came in at $4.1 million for Q1 2026 at Nuvectis Pharma, down from $5.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $5.8 million in Q3 2025 to a low of $865000.0 in Q1 2022.
• The 5-year median for Research & Development is $4.1 million (2026), against an average of $3.7 million.
• Peak annual rise in Research & Development reached 284.35% in 2022, while the deepest fall reached 40.99% in 2022.
• Nuvectis Pharma's Research & Development stood at $4.4 million in 2022, then retreated by 3.0% to $4.3 million in 2023, then grew by 5.42% to $4.5 million in 2024, then rose by 13.12% to $5.1 million in 2025, then retreated by 19.27% to $4.1 million in 2026.
• The last three Research & Development figures came in at $4.1 million (Q1 2026), $5.1 million (Q4 2025), and $5.8 million (Q3 2025), per Business Quant data.